Somatostatin Receptor–Targeted Radiopeptide Therapy with ⁹⁰Y-DOTATOC and ¹⁷⁷Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial

Abstract

(90)Y-DOTATOC and (177)Lu-DOTATOC are promising tools for treating progressive unresectable meningioma, especially in cases of high tracer uptake in the tumor.